Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

TSHA

Taysha Gene Therapies Inc

Apr 26 • 04:00PM ET

2.39

Dollar change +0.09
Percentage change 3.91	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IBB TXSS BIB ISCG ISCV IBBQ TXS ISCB

Index	-	P/E	-	EPS (ttm)	-1.34	Insider Own	31.23%	Shs Outstand	186.96M	Perf Week	5.29%
Market Cap	446.98M	Forward P/E	-	EPS next Y	-0.48	Insider Trans	0.17%	Shs Float	128.62M	Perf Month	-24.61%
Income	-111.57M	PEG	-	EPS next Q	-0.11	Inst Own	62.24%	Short Float	12.49%	Perf Quarter	61.49%
Sales	15.45M	P/S	28.93	EPS this Y	57.71%	Inst Trans	-1.76%	Short Ratio	5.79	Perf Half Y	-5.53%
Book/sh	0.40	P/B	5.96	EPS next Y	-17.13%	ROA	-56.40%	Short Interest	16.07M	Perf Year	264.00%
Cash/sh	0.77	P/C	3.10	EPS next 5Y	-	ROE	-294.04%	52W Range	0.50 - 3.89	Perf YTD	35.03%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-137.69%	ROI	-83.01%	52W High	-38.56%	Beta	0.37
Dividend TTM	-	Quick Ratio	4.06	Sales past 5Y	129.39%	Gross Margin	86.86%	52W Low	378.00%	ATR (14)	0.26
Dividend Ex-Date	-	Current Ratio	4.06	EPS Y/Y TTM	64.68%	Oper. Margin	-461.94%	RSI (14)	44.44	Volatility	8.79% 9.49%
Employees	52	Debt/Eq	0.82	Sales Y/Y TTM	517.55%	Profit Margin	-722.06%	Recom	1.11	Target Price	6.83
Option/Short	Yes / Yes	LT Debt/Eq	0.79	EPS Q/Q	125.84%	Payout	-	Rel Volume	0.32	Prev Close	2.30
Sales Surprise	23.41%	EPS Surprise	331.76%	Sales Q/Q	44.04%	Earnings	Mar 19 AMC	Avg Volume	2.77M	Price	2.39
SMA20	-10.56%	SMA50	-7.87%	SMA200	14.62%	Trades		Volume	890,150	Change	3.91%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-09-24	Initiated	Piper Sandler	Overweight	$9
Feb-01-23	Downgrade	Jefferies	Buy → Hold	$14 → $1.50
Jan-27-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$23 → $3
Nov-09-22	Downgrade	Goldman	Buy → Neutral	$16 → $3
Mar-09-22	Initiated	Robert W. Baird	Outperform	$26
Mar-01-22	Initiated	Wells Fargo	Overweight	$25
Feb-18-22	Initiated	SMBC Nikko	Outperform	$25
Dec-16-21	Initiated	Guggenheim	Buy	$28
Jul-16-21	Initiated	Needham	Buy	$45
Jun-24-21	Initiated	Truist	Buy	$60
Jun-15-21	Initiated	BTIG Research	Buy	$44
Jun-09-21	Initiated	Wedbush	Outperform	$31
Jun-08-21	Initiated	JMP Securities	Mkt Outperform	$40
May-19-21	Initiated	Cantor Fitzgerald	Overweight	$44
May-11-21	Resumed	Jefferies	Buy	$34 → $45
Feb-24-21	Initiated	William Blair	Outperform
Jan-05-21	Initiated	Oppenheimer	Outperform	$42
Oct-19-20	Initiated	Morgan Stanley	Overweight	$29
Oct-19-20	Initiated	Jefferies	Buy	$34
Oct-19-20	Initiated	Goldman	Buy	$31

Show Previous Ratings

Apr-15-24 05:30AM	Certain Biotech Investors Get an Early Look at Results. Is That Fair? (The Wall Street Journal) -9.52%
Apr-05-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-20-24 11:19AM	Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2023 Earnings Call Transcript (Insider Monkey) +31.56%
08:01AM	Q4 2023 Taysha Gene Therapies Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-19-24 08:53PM	TSHA Stock Earnings: Taysha Gene Therapies Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) +5.63%
04:01PM	Loading…
04:01PM	Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates (GlobeNewswire)
Mar-14-24 04:26PM	Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19 (GlobeNewswire) -5.31%
Mar-01-24 05:08PM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-29-24 08:00AM	Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome (GlobeNewswire) +19.70%
Feb-15-24 04:01PM	Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs (GlobeNewswire) +8.90%
Feb-02-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-31-24 02:23PM	7 Micro-Cap Stocks That Could Majorly Surprise Investors (InvestorPlace)
Jan-22-24 08:00AM	Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference (GlobeNewswire)
Jan-15-24 09:30AM	3 Growth Stocks That Could Go Parabolic in 2024 (Motley Fool)
Jan-10-24 08:00AM	Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome (GlobeNewswire) -7.29%
08:00AM	Loading…
Jan-05-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-19-23 07:30AM	Trinity Capital Inc. Provides $40 Million Term Loan to Taysha Gene Therapies (PR Newswire)
Nov-29-23 08:00AM	Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients (GlobeNewswire)
Nov-15-23 02:00PM	Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q3 2023 Earnings Call Transcript (Insider Monkey) +26.32%
12:52PM	Q3 2023 Taysha Gene Therapies Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-14-23 06:35PM	Taysha Gene Therapies Inc (TSHA) Reports Q3 2023 Financial Results and Clinical Progress (GuruFocus.com)
04:08PM	Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates (GlobeNewswire)
Nov-07-23 08:00AM	Taysha Gene Therapies to Release Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 14 (GlobeNewswire)
Oct-24-23 08:00AM	Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress (GlobeNewswire)
Oct-10-23 08:00AM	Taysha Gene Therapies Announces Two Poster Presentations on TSHA-102 in Rett Syndrome at Upcoming European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress (GlobeNewswire) -5.97%
Sep-26-23 08:00AM	Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome (GlobeNewswire)
Sep-19-23 04:01PM	Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy (GAN) (GlobeNewswire) +5.16%
Sep-05-23 09:55AM	Taysha Gene Therapies, Inc. (TSHA) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
Sep-04-23 03:04PM	3 Small-Cap Stocks to Sell in September Before They Crash & Burn (InvestorPlace)
Aug-24-23 08:00AM	Taysha Gene Therapies Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome (GlobeNewswire) +5.41%
01:54AM	Loading…
Aug-15-23 01:54AM	Q2 2023 Taysha Gene Therapies Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-23 07:02AM	Taysha Gene Therapies Reports Initial Clinical Data from First Adult Rett Syndrome Patient Dosed in REVEAL Phase 1/2 Trial and Provides Corporate Update with Second Quarter 2023 Financial Results (GlobeNewswire) +188.23%
07:00AM	Taysha Gene Therapies Announces $150 Million Private Placement Financing (GlobeNewswire)
Jul-31-23 08:00AM	Taysha Gene Therapies Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1/2 Trial in Rett Syndrome (GlobeNewswire)
Jul-18-23 07:08AM	Taysha Gene Therapies Insiders Added US$3.0m Of Stock To Their Holdings (Simply Wall St.)
Jun-28-23 08:00AM	Taysha Gene Therapies Provides Clinical Updates for Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at R&D Day (GlobeNewswire)
Jun-15-23 08:00AM	Taysha Gene Therapies to Host Virtual R&D Day on Lead Clinical Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome (GlobeNewswire)
Jun-05-23 08:00AM	Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial Under Investigation for the Treatment of Rett Syndrome (GlobeNewswire) +5.06%
May-19-23 12:54PM	Taysha Gene Therapies Touts Encouraging Preclinical Data From Rett Syndrome Candidate (Benzinga) +5.64%
08:00AM	Taysha Gene Therapies Presents Preclinical Data on TSHA-102 for Rett Syndrome Demonstrating Cellular Regulation of MeCP2 Expression in Key Mouse Models at the American Society of Gene and Cell Therapy 26th Annual Meeting (GlobeNewswire)
May-16-23 11:41AM	Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-12-23 10:15AM	Q1 2023 Taysha Gene Therapies Inc Earnings Call (Thomson Reuters StreetEvents) -5.30%
May-11-23 04:01PM	Taysha Gene Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -5.47%
May-04-23 08:00AM	Taysha Gene Therapies to Release First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11 (GlobeNewswire) +5.20%
Apr-27-23 04:52PM	Taysha Gene Therapies Announces Presentation on New Preclinical Data for TSHA-102 in Rett Syndrome at Upcoming American Society of Gene and Cell Therapy 26th Annual Meeting (GlobeNewswire)
Apr-15-23 08:24AM	Even after rising 30% this past week, Taysha Gene Therapies (NASDAQ:TSHA) shareholders are still down 84% over the past year (Simply Wall St.)
Mar-30-23 06:08AM	Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2022 Earnings Call Transcript (Insider Monkey) +11.37%
Mar-28-23 04:01PM	Taysha Gene Therapies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -6.19%
Mar-15-23 04:01PM	Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 28 (GlobeNewswire)
Feb-14-23 05:32PM	How patients' families pushed rare-disease therapy to cusp of clinical trial until biotech's cash halted progress (American City Business Journals)
Feb-08-23 05:42AM	A Taysha Gene Therapies, Inc. (NASDAQ:TSHA) insider increased their holdings by 28% last year (Simply Wall St.)
Jan-31-23 04:01PM	Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy and a 2023 Corporate Outlook (GlobeNewswire) +6.49%
Jan-24-23 02:32PM	Biotech signals potential pullback from 200-job Durham plant (American City Business Journals)
Dec-19-22 02:05PM	Dallas-based Taysha Gene Therapies names board chair as new CEO (American City Business Journals) -9.35%
Dec-16-22 06:19PM	Taysha Gene Therapies Announces Executive Leadership Changes (GlobeNewswire) -6.96%
Dec-01-22 09:55AM	Taysha Gene Therapies, Inc. (TSHA) Could Find Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-29-22 04:01PM	Taysha Gene Therapies to Participate in JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-08-22 07:00AM	Taysha Gene Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +10.00%
Nov-03-22 08:26PM	These 2 Stocks May Be Reaching a Bottom; Insiders Are Buying the Dip (TipRanks) +11.43%
Nov-02-22 07:00AM	Taysha Gene Therapies to Release Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 8 (GlobeNewswire)
Oct-26-22 07:54PM	Taysha Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -27.52%
11:05AM	3 Small-Cap Stocks That Hold Plenty of Promise Heading Into 2023 (TheStreet.com)
06:13AM	Positive week for Taysha Gene Therapies, Inc. (NASDAQ:TSHA) institutional investors who lost 82% over the past year (Simply Wall St.)
Oct-25-22 04:01PM	Taysha Gene Therapies Announces Proposed Public Offering of Common Stock (GlobeNewswire) +97.35%
03:55PM	Dallas-based Taysha Gene Therapies to receive $50M investment from Japanese pharmaceutical company (American City Business Journals)
09:31AM	Thinking about buying stock in Taysha Gene Therapies, Nio, Traeger, Amprius Technologies, or Sellas Life Sciences? (PR Newswire)
08:15AM	Astellas Pharma Invests $50M To Support Taysha's Gene Therapy Programs (Benzinga)
Oct-24-22 07:35PM	Taysha Gene Therapies to Host Conference Call to Discuss Astellas Pharmas Strategic Investment to Support the Development of Tayshas AAV-based Gene Therapy Programs (GlobeNewswire)
07:30PM	Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha's AAV-based Gene Therapy Programs (PR Newswire)
Oct-06-22 07:00AM	Taysha Gene Therapies Announces Presentations at the Upcoming 29th Annual Meeting of the European Society of Gene & Cell Therapy (ESGCT) (GlobeNewswire)
Aug-29-22 07:35AM	Having purchased US$2.3m worth of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) stock, the recent 12% pullback is not what insiders may have expected (Simply Wall St.)
Aug-12-22 08:30AM	Taysha Gene Therapies, Inc. (TSHA) Q2 2022 Earnings Call Transcript (Motley Fool)
Aug-11-22 07:00AM	Taysha Gene Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -19.06%
Aug-09-22 05:22PM	Taysha Gene Therapies to Release Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11 (GlobeNewswire) +5.24%
Aug-01-22 07:00AM	Taysha Gene Therapies to Participate in Upcoming August Investor Conferences (GlobeNewswire)
Jul-19-22 08:39AM	Are Investors Undervaluing Taysha Gene Therapies, Inc. (NASDAQ:TSHA) By 33%? (Simply Wall St.)
Jul-06-22 07:00AM	Taysha Gene Therapies to Participate in Upcoming William Blair Biotech Focus Conference 2022 (GlobeNewswire) +8.52%
Jun-13-22 08:39AM	Taysha Gene Therapies Announces Annual Stockholder Meeting (GlobeNewswire) -17.22%
Jun-02-22 07:00AM	Taysha Gene Therapies to Participate in Upcoming June Investor Conferences and Convention (GlobeNewswire)
May-16-22 08:00PM	Taysha Gene Therapies, Inc. (TSHA) Q1 2022 Earnings Call Transcript (Motley Fool)
07:00AM	Taysha Gene Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
May-11-22 07:00AM	Taysha Gene Therapies to Release First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 16 (GlobeNewswire) -14.48%
May-10-22 07:00AM	Taysha Gene Therapies Announces Presentations at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy (GlobeNewswire)
May-07-22 10:57AM	Do Insiders Own Lots Of Shares In Taysha Gene Therapies, Inc. (NASDAQ:TSHA)? (Simply Wall St.)
May-03-22 07:00AM	Taysha Gene Therapies Receives Orphan Drug Designation from the European Commission for TSHA-120 for the Treatment of Giant Axon Neuropathy (GAN) (GlobeNewswire) +8.88%
Apr-25-22 07:00AM	Taysha Gene Therapies Announces Oral Presentations at the Upcoming 2022 IRSF Rett Syndrome Scientific Symposium and the ASCEND National Summit (GlobeNewswire)
Apr-18-22 08:00AM	Taysha Gene Therapies to Participate in Upcoming Chardan Genetic Medicines and Cell Therapy Manufacturing Summit (GlobeNewswire) -7.40%
Apr-04-22 10:16AM	Wall Street Analysts Believe Taysha Gene Therapies, Inc. (TSHA) Could Rally 608%: Here's is How to Trade (Zacks) +6.78%
Mar-31-22 06:29PM	Why this Dallas biotech firm is cutting roughly 35% of its headcount (American City Business Journals) +6.02%
05:30PM	Taysha Gene Therapies, Inc. (TSHA) Q4 2021 Earnings Call Transcript (Motley Fool)
01:31PM	Taysha Gene Therapies Lays Off 35% Of staff, Narrows R&D Focus (Benzinga)
07:00AM	Taysha Gene Therapies Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (Business Wire)
Mar-29-22 07:00AM	Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-102 in Rett Syndrome (Business Wire)
Mar-24-22 07:00AM	Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 31 (Business Wire)
Mar-23-22 07:00AM	Taysha Gene Therapies to Participate in Upcoming April Investor Healthcare Conferences (Business Wire)
Mar-16-22 11:14AM	3 Strong Buy Stocks Under $10 That Could See 100% Gains (or More) (TipRanks) +10.28%
Mar-08-22 07:00AM	Taysha Gene Therapies to Participate in the Oppenheimer 32nd Annual Virtual Healthcare Conference (Business Wire)
Feb-10-22 04:50PM	Two Insider Moonshots Rising on Sudden Buying (InvestorPlace) -5.24%
09:47AM	The Independent Director of Taysha Gene Therapies, Inc. (NASDAQ:TSHA), Paul Manning, Just Bought 3.4% More Shares (Simply Wall St.)
Feb-09-22 05:00PM	Taysha Gene Therapies Announces Positive Safety Data from UT Southwestern-Sponsored Clinical Trial for the Treatment of CLN7 Batten Disease at 18th Annual WORLDSymposium (Business Wire)

Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Manning Paul B	10% Owner	Nov 17 '23	Buy	1.63	100,000	163,000	16,566,667	Nov 20 07:35 AM
Alam Kamran	Chief Financial Officer	Aug 24 '23	Sale	2.33	33,000	76,890	258,042	Aug 25 04:30 PM
Manning Paul B	10% Owner	Aug 16 '23	Buy	0.90	16,466,667	14,820,000	16,466,667	Aug 16 08:57 PM
Nolan Sean P.	Chief Executive Officer	Aug 16 '23	Buy	0.90	444,444	400,000	1,535,545	Aug 16 08:52 PM
Stalfort John A III	Director	Aug 16 '23	Buy	0.90	388,889	350,000	884,290	Aug 16 08:53 PM
Stalfort John A III	Director	Aug 16 '23	Buy	0.90	388,889	350,000	999,381	Aug 16 08:53 PM
Donenberg Phillip B.	Director	Aug 16 '23	Buy	0.90	111,111	100,000	114,111	Aug 16 08:51 PM
Session R.A. II	10% Owner	Jul 13 '23	Sale	0.70	5,344	3,741	8,871,747	Jul 14 04:00 PM
Session R.A. II	10% Owner	Jul 12 '23	Sale	0.71	80,528	57,030	8,877,091	Jul 14 04:00 PM
Session R.A. II	10% Owner	Jun 23 '23	Sale	0.70	18,100	12,735	8,957,619	Jun 26 04:46 PM
Session R.A. II	10% Owner	Jun 22 '23	Sale	0.70	10,508	7,384	8,975,719	Jun 26 04:46 PM
Session R.A. II	10% Owner	Jun 21 '23	Sale	0.70	138,962	97,635	8,986,227	Jun 22 04:00 PM
Session R.A. II	10% Owner	Jun 20 '23	Sale	0.71	295,653	210,209	9,125,189	Jun 22 04:00 PM
Nagendran Sukumar	President and Head of R&D	May 16 '23	Buy	0.68	5,000	3,400	34,226	May 18 04:44 PM

Open in Screener

VRCA

Verrica Pharmaceuticals Inc

Apr 26 • 04:00PM ET

6.87

Dollar change +0.22
Percentage change 3.31	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

VRCA Verrica Pharmaceuticals Inc daily Stock Chart

Held by: VTI IWM VXF IWO VTWO RYLD IWC VTWG GSSC AVSC

Index	RUT	P/E	-	EPS (ttm)	-1.46	Insider Own	40.00%	Shs Outstand	42.41M	Perf Week	-1.58%
Market Cap	291.43M	Forward P/E	-	EPS next Y	-0.75	Insider Trans	12.78%	Shs Float	25.45M	Perf Month	21.59%
Income	-67.00M	PEG	-	EPS next Q	-0.45	Inst Own	42.47%	Short Float	15.07%	Perf Quarter	18.65%
Sales	5.12M	P/S	56.92	EPS this Y	-2.53%	Inst Trans	-9.35%	Short Ratio	27.88	Perf Half Y	82.71%
Book/sh	0.47	P/B	14.74	EPS next Y	50.82%	ROA	-106.07%	Short Interest	3.84M	Perf Year	11.17%
Cash/sh	1.64	P/C	4.19	EPS next 5Y	-	ROE	-224.08%	52W Range	2.86 - 7.76	Perf YTD	-6.15%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-0.97%	ROI	-103.75%	52W High	-11.41%	Beta	1.85
Dividend TTM	-	Quick Ratio	4.49	Sales past 5Y	-13.60%	Gross Margin	75.34%	52W Low	140.21%	ATR (14)	0.33
Dividend Ex-Date	-	Current Ratio	4.55	EPS Y/Y TTM	-78.42%	Oper. Margin	-1233.82%	RSI (14)	61.17	Volatility	4.53% 5.61%
Employees	100	Debt/Eq	2.30	Sales Y/Y TTM	-43.27%	Profit Margin	-1307.47%	Recom	1.00	Target Price	13.67
Option/Short	Yes / Yes	LT Debt/Eq	2.27	EPS Q/Q	-268.07%	Payout	-	Rel Volume	0.81	Prev Close	6.65
Sales Surprise	103.86%	EPS Surprise	5.69%	Sales Q/Q	2823.53%	Earnings	Feb 29 BMO	Avg Volume	137.59K	Price	6.87
SMA20	2.42%	SMA50	18.50%	SMA200	36.56%	Trades		Volume	111,046	Change	3.31%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-25-23	Upgrade	Needham	Hold → Buy	$10
Mar-22-23	Initiated	Jefferies	Buy	$10
Feb-13-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$4 → $11
May-25-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$16 → $4
May-14-21	Initiated	RBC Capital Mkts	Outperform	$19
Dec-24-20	Reiterated	H.C. Wainwright	Buy	$18 → $21
Jul-15-20	Downgrade	BofA Securities	Buy → Neutral
Jun-30-20	Reiterated	H.C. Wainwright	Buy	$24 → $18
Jun-24-20	Initiated	Northland Capital	Outperform	$21
Mar-24-20	Initiated	Needham	Buy	$20
Feb-21-19	Initiated	H.C. Wainwright	Buy	$20

Show Previous Ratings

Apr-27-24 06:00AM	Bragar Eagel & Squire is Investigating Certain Officers and Directors of Caribou, Verrica, and Playstudios on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm (GlobeNewswire)
Apr-02-24 07:30AM	Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-26-24 07:30AM	Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDA (GlobeNewswire) +5.14%
Mar-01-24 09:10AM	Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call Transcript (Insider Monkey) +5.31%
Feb-29-24 08:11AM	Verrica Pharmaceuticals Inc (VRCA) Reports Fourth Quarter and Full-Year 2023 Financial Results (GuruFocus.com) -7.87%
07:30AM	Loading…
07:30AM	Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results (GlobeNewswire)
Feb-27-24 07:30AM	Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference (GlobeNewswire)
Feb-22-24 07:30AM	Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024 (GlobeNewswire)
Feb-05-24 07:30AM	Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition (GlobeNewswire) -7.58%
Jan-29-24 07:30AM	Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH from Centers for Medicare and Medicaid Services (GlobeNewswire)
Jan-22-24 07:44PM	7 Potential Short-Squeeze Stocks Poised for Rapid Gains (InvestorPlace)
Jan-05-24 07:30AM	Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma (GlobeNewswire)
Jan-04-24 07:30AM	Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH for the Treatment of Common Warts (GlobeNewswire)
Jan-03-24 07:30AM	Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH (GlobeNewswire)
Dec-15-23 01:49PM	Why Is Verrica Pharmaceuticals (VRCA) Stock Up 40% Today? (InvestorPlace) +61.97%
06:00AM	Loading…
06:00AM	Verrica Pharmaceuticals' Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan (GlobeNewswire)
Nov-11-23 10:13AM	Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 08:00AM	Verrica Pharmaceuticals Announces Presentation at the Jefferies Global Healthcare Conference in London (GlobeNewswire)
Nov-09-23 07:30AM	Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results (GlobeNewswire) -9.83%
Oct-25-23 07:00AM	Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023 (GlobeNewswire)
Sep-27-23 08:00AM	Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023 (GlobeNewswire)
Aug-31-23 08:00AM	Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-24-23 08:30AM	Verrica Pharmaceuticals Announces First Sale of YCANTH to FFF Enterprises (GlobeNewswire)
Aug-23-23 07:30AM	Verrica Issues Statement in Support of FDAs Warning Letters to Manufacturers and Retailers for Producing and Selling Unapproved Products for the Treatment of Molluscum Contagiosum (GlobeNewswire)
Aug-10-23 04:05PM	Verrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology (AAD) 2023 Innovation Academy Meeting (GlobeNewswire)
Aug-08-23 07:30AM	Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-03-23 07:30AM	Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Associations (AAD) 2023 Innovation Academy Meeting (GlobeNewswire)
Jul-27-23 06:06AM	Verrica Pharmaceuticals Chairman of the Board Acquires 1.3% More Stock (Simply Wall St.)
Jul-26-23 04:05PM	Verrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed (GlobeNewswire)
Jul-25-23 07:16AM	Daily Vickers Top Buyers & Sellers for 07/25/2023 (Argus Research)
03:16PM	Loading…
Jul-24-23 03:16PM	Why Shares of Verrica Pharmaceuticals Are Plummeting on Monday (Motley Fool) -31.46%
07:00AM	Following FDA Approval of YCANTH for the Treatment of Molluscum Contagiosum, Verrica Pharmaceuticals Enters into Non-Binding Term Sheet for up to $125 Million Debt Financing; Company to Host Conference Call and Webcast This Morning at 8:30 am ET (GlobeNewswire)
Jul-21-23 04:47PM	UPDATE 2-Verrica's drug gets US nod as first treatment for a type of skin infection (Reuters)
04:30PM	US FDA approves Verrica's skin disease treatment (Reuters)
04:24PM	Verrica Pharmaceuticals Announces FDA Approval of YCANTH (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum (GlobeNewswire)
Jul-17-23 07:22AM	With a 39% stake, Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) insiders have a lot riding on the company (Simply Wall St.) +6.43%
Jul-12-23 03:16AM	Net Asset Value(s) (Business Wire)
May-31-23 07:00AM	Verrica Pharmaceuticals Announces Presentation at the Jefferies Healthcare Conference in New York (GlobeNewswire) +6.58%
May-30-23 12:34PM	We're Not Worried About Verrica Pharmaceuticals' (NASDAQ:VRCA) Cash Burn (Simply Wall St.) -7.48%
May-10-23 07:30AM	Verrica Pharmaceuticals Announces Presentation at the RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
06:11AM	Verrica Pharmaceuticals First Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
May-09-23 07:30AM	Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-05-23 09:07AM	The past three years for Verrica Pharmaceuticals (NASDAQ:VRCA) investors has not been profitable (Simply Wall St.)
Apr-26-23 08:01PM	7 Biotech Stocks With Huge Return Potential for Long-Term Investors (InvestorPlace)
Apr-12-23 07:00AM	Verrica Pharmaceuticals Announces Dosing of the First Patient in Part 2 of Phase 2 Study Evaluating VP-315 for the Treatment of Basal Cell Carcinoma (GlobeNewswire)
Apr-11-23 07:00AM	Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-06-23 07:30AM	Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results (GlobeNewswire)
Feb-28-23 04:05PM	Verrica Pharmaceuticals Announces Participation at The Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-27-23 04:05PM	Verrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102 for the Treatment of Molluscum Contagiosum (GlobeNewswire) -5.47%
Feb-22-23 11:49AM	Verrica Pharmaceuticals expects $32.5M from the sale of stock and warrants (American City Business Journals)
Feb-21-23 07:22AM	Verrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +5.56%
Feb-17-23 06:43PM	12 Most Promising Micro-Cap Stocks According to Analysts (Insider Monkey) +8.34%
Feb-14-23 10:15AM	2 Breakout Growth Stocks to Buy for the Long Haul (Motley Fool)
Jan-24-23 07:30AM	Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum (GlobeNewswire)
07:16AM	Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) insiders have significant skin in the game with 40% ownership (Simply Wall St.)
Jan-04-23 07:30AM	Verrica Pharmaceuticals Announces the Successful Technology Transfer of Bulk Solution Manufacturing of VP-102 to Piramal Pharma Solutions (GlobeNewswire) +14.93%
Jan-01-23 08:16AM	Bullish insiders bet US$11m on Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) (Simply Wall St.)
Dec-12-22 12:07PM	We're Not Very Worried About Verrica Pharmaceuticals' (NASDAQ:VRCA) Cash Burn Rate (Simply Wall St.)
Nov-26-22 07:00AM	Investors in Verrica Pharmaceuticals (NASDAQ:VRCA) have unfortunately lost 83% over the last three years (Simply Wall St.)
Nov-07-22 04:05PM	Verrica Pharmaceuticals Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Aug-31-22 04:30PM	Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +8.89%
Aug-17-22 07:53AM	Is Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Popular Amongst Insiders? (Simply Wall St.)
Aug-11-22 07:30AM	Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results (GlobeNewswire) +5.22%
Aug-04-22 01:38PM	Zoetis' (ZTS) Q2 Earnings Miss Estimates, Revenues Up (Zacks)
12:34PM	Pacira's (PCRX) Q2 Earnings Miss Estimates, Revenues Rise Y/Y (Zacks)
Aug-03-22 12:02PM	United Therapeutics (UTHR) Q2 Earnings Miss Estimates, Revenues Up (Zacks)
Aug-01-22 07:30AM	Verrica Pharmaceuticals Announces Start of Phase 3 Trial of VP-102 for the Treatment of Molluscum Contagiosum by Torii Pharmaceutical Co., Ltd. in Japan (GlobeNewswire) -6.35%
Jul-20-22 12:00PM	Verrica Pharmaceuticals Inc. (VRCA) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks) +5.61%
Jul-18-22 11:43AM	Endo (ENDP) Inks Deal to Develop Rare Disease Drug in Canada (Zacks)
Jul-07-22 06:10AM	Insider Buying: The Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Chairman of the Board Just Bought 46% More Shares (Simply Wall St.) +10.62%
Jul-06-22 09:31AM	Thinking about buying stock in Verrica Pharmaceuticals, Scisparc, Adverum Biotechnologies, OneConnect Financial Tech, or Alaunos Therapeutics? (PR Newswire) +9.20%
Jul-01-22 09:36AM	Lab Notes: Verrica continues push for skin disorder drug, raising $25M; Windtree weighing options (American City Business Journals) +13.02%
Jun-29-22 09:23PM	Verrica Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -6.87%
04:01PM	Verrica Announces Proposed Public Offering of Common Stock (GlobeNewswire)
03:26PM	Analysts Still Believe Verrica's Ycanth Is Approvable Despite FDA Response Letter (Benzinga)
Jun-28-22 07:30AM	Verrica Pharmaceuticals Holds Type A Meeting with FDA for VP-102 for Molluscum Contagiosum (GlobeNewswire) +6.88%
Jun-17-22 09:35AM	Down 65% in 4 Weeks, Here's Why You Should You Buy the Dip in Verrica Pharmaceuticals Inc. (VRCA) (Zacks) +8.70%
Jun-13-22 09:55AM	Here's Why Verrica Pharmaceuticals Inc. (VRCA) Could be Great Choice for a Bottom Fisher (Zacks)
Jun-05-22 08:42AM	Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) insiders recover some losses but still US$354k away from matching original investment (Simply Wall St.)
Jun-01-22 09:35AM	Here's Why Verrica Pharmaceuticals Inc. (VRCA) is Poised for a Turnaround After Losing 70.4% in 4 Weeks (Zacks) -6.22%
May-26-22 03:37PM	Verrica (VRCA) Down 64% as Molluscum Drug Gets CRL From FDA (Zacks)
May-25-22 03:14PM	RBC Capital Slashes Verrica's Price Target After Third Rejection - What's Next? (Benzinga) -63.85%
08:18AM	Verrica's stock slides after getting second complete response letter from FDA (MarketWatch)
06:39AM	Why Verrica Pharma Shares Are Plunging Today (Benzinga)
May-24-22 09:12PM	UPDATE 1-U.S. FDA declines to authorize Verrica's viral skin disease treatment (Reuters) -11.75%
08:00PM	Verrica Receives Complete Response Letter from the FDA for its NDA for VP-102 as a Direct Result of Deficiencies at General Reinspection of Sterling Pharmaceuticals Services, LLC (GlobeNewswire)
May-17-22 11:53AM	KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M (Zacks)
May-16-22 09:35AM	After Plunging 28.5% in 4 Weeks, Here's Why the Trend Might Reverse for Verrica Pharmaceuticals Inc. (VRCA) (Zacks) +6.89%
May-13-22 09:35AM	Here's Why Verrica Pharmaceuticals Inc. (VRCA) is Poised for a Turnaround After Losing 31.6% in 4 Weeks (Zacks)
May-11-22 06:35AM	7 Biotech Stocks With Key Catalysts for May (InvestorPlace) -6.46%
May-09-22 07:30AM	Verrica Pharmaceuticals Reports First Quarter 2022 Financial Results (GlobeNewswire)
Apr-08-22 12:15PM	Lab Notes: Venatorx closes Series C financing; Ocugen takes 'critical' step in clinical trial (American City Business Journals)
Apr-07-22 07:30AM	Verrica Pharmaceuticals Announces Participation in the 21st Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-05-22 07:30AM	Verrica Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma (GlobeNewswire)
Mar-06-22 06:45AM	Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Just Reported And Analysts Have Been Cutting Their Estimates (Simply Wall St.)
Mar-02-22 04:05PM	Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results (GlobeNewswire)
Feb-24-22 07:30AM	Verrica Pharmaceuticals Announces Participation in the 42nd Annual Cowen Virtual Healthcare Conference (GlobeNewswire)
Dec-17-21 05:23AM	Need To Know: The Consensus Just Cut Its Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Estimates For 2022 (Simply Wall St.)
Dec-15-21 04:05PM	Verrica Pharmaceuticals Announces Acceptance by FDA of NDA Resubmission for VP-102 for the Treatment of Molluscum Contagiosum (GlobeNewswire)
Dec-08-21 05:01AM	Chairman of the Board Paul Manning Just Bought A Handful Of Shares In Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) (Simply Wall St.)

Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 29 '23	Buy	7.24	115,774	838,204	7,099,182	Dec 29 05:27 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 28 '23	Buy	7.08	126,116	892,901	6,983,408	Dec 29 05:27 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 27 '23	Buy	7.20	79,726	574,027	6,857,292	Dec 29 05:27 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 26 '23	Buy	6.49	54,652	354,691	6,777,566	Dec 26 07:21 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 22 '23	Buy	6.67	250,000	1,667,500	6,722,914	Dec 26 07:21 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 21 '23	Buy	6.17	200,000	1,234,000	6,472,914	Dec 26 07:21 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 19 '23	Buy	5.36	277,008	1,484,763	6,272,914	Dec 19 05:52 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 18 '23	Buy	5.41	456,923	2,471,953	5,995,906	Dec 19 05:52 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 15 '23	Buy	5.97	500,000	2,985,000	5,538,983	Dec 19 05:52 PM
Hayes Christopher G.	Chief Legal Officer	Nov 15 '23	Sale	2.97	11,558	34,327	123,226	Nov 16 04:32 PM
White Ted	President and CEO	Nov 15 '23	Sale	2.97	11,558	34,327	170,090	Nov 16 04:33 PM
Bonaccorso Joe	Chief Commercial Officer	Nov 15 '23	Sale	2.97	11,266	33,460	92,392	Nov 16 04:49 PM
Kohler Terry	Chief Financial Officer	Nov 15 '23	Sale	2.97	9,632	28,607	34,416	Nov 16 04:34 PM
Goldenberg Gary	Chief Medical Officer	Nov 15 '23	Sale	2.97	3,036	9,017	86,257	Nov 16 04:35 PM
Hayes Christopher G.	Chief Legal Officer	Nov 14 '23	Sale	2.93	22,141	64,873	134,784	Nov 16 04:32 PM
White Ted	President and CEO	Nov 14 '23	Sale	2.93	22,141	64,873	181,648	Nov 16 04:33 PM
Bonaccorso Joe	Chief Commercial Officer	Nov 14 '23	Sale	2.93	21,580	63,229	103,658	Nov 16 04:49 PM
Kohler Terry	Chief Financial Officer	Nov 14 '23	Sale	2.93	18,452	54,064	44,048	Nov 16 04:34 PM
Goldenberg Gary	Chief Medical Officer	Nov 14 '23	Sale	2.93	5,817	17,044	89,293	Nov 16 04:35 PM
Manning Paul B	Director	Jul 24 '23	Buy	5.02	200,000	1,004,000	7,851,128	Jul 24 06:47 PM
White Ted	President and CEO	Jul 24 '23	Sale	4.83	50,677	244,770	128,789	Jul 25 04:18 PM
Bonaccorso Joe	Chief Commercial Officer	Jul 24 '23	Sale	4.83	38,262	184,805	62,738	Jul 25 04:22 PM
Hayes Christopher G.	Chief Legal Officer	Jul 24 '23	Sale	4.83	33,789	163,201	81,925	Jul 25 04:25 PM
Goldenberg Gary	Chief Medical Officer	Jul 24 '23	Sale	4.83	28,699	138,616	70,110	Jul 25 04:23 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

TSHA

Taysha Gene Therapies Inc

VRCA

Verrica Pharmaceuticals Inc

Upgrade your FINVIZ experience